CoChat

Multifunctional nanocomposites utilizing ruthenium (II) complex/manganese (IV) dioxide nanoparticle for synergistic reinforcing radioimmunotherapy

Open access
Peng, Jian, Quan, Dong-Ling, Yang, Guang, Wei, Lin-Tao, Yang, Zhuan, Dong, Zhi-Ying, Zou, Yi-Ming, Hou, Ying-Ke, Chen, Jin-Xiang, Lv, Lin, Sun, Bin · 2024 · Journal of Nanobiotechnology

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Abstract

Radiotherapy (RT) stands as a frontline treatment modality in clinical breast oncology, yet challenges like ROS reduction, high toxicity, non-selectivity, and hypoxia hinder efficacy. Additionally, RT administered at different doses can induce varying degrees of radioimmunotherapy. High doses of radiation (>10 Gy) may result in immune suppression, while moderate doses (4–10 Gy), although capable of mitigating the immune suppression caused by high-dose radiation, are often insufficient in effectively killing tumor cells. Therefore, enhancing the generation of ROS and ameliorating the tumor hypoxic immune-suppressive microenvironment at moderate radiation doses could potentially drive radiation-induced immune responses, offering a fundamental solution to the limitations of RT. In this study, a novel multifunctional nanoplatform, RMLF, integrating a Ru (II) complex into folate-functionalized liposomes with BSA-MnO 2 nanoparticles was proposed. Orthogonal experimental optimization enhances radiosensitization via increasing accumulation in cancer cells, elevating ROS, and contributing to a dual enhancement of the cGAS-STING-dependent type I IFN signaling pathway, aimed to overcome the insufficient DAMPs typically seen in the conventional RT at 4 Gy. Such a strategy effectively activated cytotoxic T lymphocytes for infiltration into tumor tissues and promoted the polarization of tumor-associated macrophages from the M2 to M1 phenotype, substantially bolstering immune memory responses. This pioneering approach represents the first use of a ruthenium complex in radioimmunotherapy, activating the cGAS-STING pathway to amplify immune responses, overcome RT resistance, and extend immunotherapeutic potential.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12951-024-03013-2

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Scheme 1 Synthesis process of RMLF (a) and its application in radioimmunotherapy of breast cancer (b)
Scheme 1 Synthesis process of RMLF (a) and its application in radioimmunotherapy of breast cancer (b)CC BY-NC-ND · PubMed Central
Fig. 1 Characterizations of RMLF. (a) The fluorescence spectra of RL (10 µM RudZ) and RudZ (10 µM) in Tris·HCl buffer (Ex 450 nm/Em 500–800 nm). And the difference of fluorescence intensity between RudZ (I0) and RL (I) at 630 nm (inset). (b) Fluorescent quenching of RL (10 µM RudZ) by methanol at various times points. And the graph of fluorescence intensity over time at 630 nm. I0, fluorescence intensity of the solution at 0 min; I, fluorescence intensity of the solution at 0–30 min (inset). (c) IFM images of RudZ, Lipo, and RMLF (10 µM RudZ). The red fluorescence is derived from RudZ in the lipid bilayer. The scale bar represents 100 μm. (d) XRD spectrum of simulated MnO2, MnB and RMLF. (e) XPS spectrum of RMLF. (f) TEM images of RMLF (scale bar: 200 nm,50 nm). (g, h, i) Size distribution, zeta potential and PDI analysis of Lipo, MnB, RudZ, RL, RML and RMLF (n = 3)
Fig. 1 Characterizations of RMLF. (a) The fluorescence spectra of RL (10 µM RudZ) and RudZ (10 µM) in Tris·HCl buffer (Ex 450 nm/Em 500–800 nm). And the difference of fluorescence intensity between RudZ (I0) and RL (I) at 630 nm (inset). (b) Fluorescent quenching of RL (10 µM RudZ) by methanol at various times points. And the graph of fluorescence intensity over time at 630 nm. I0, fluorescence intensity of the solution at 0 min; I, fluorescence intensity of the solution at 0–30 min (inset). (c) IFM images of RudZ, Lipo, and RMLF (10 µM RudZ). The red fluorescence is derived from RudZ in the lipid bilayer. The scale bar represents 100 μm. (d) XRD spectrum of simulated MnO2, MnB and RMLF. (e) XPS spectrum of RMLF. (f) TEM images of RMLF (scale bar: 200 nm,50 nm). (g, h, i) Size distribution, zeta potential and PDI analysis of Lipo, MnB, RudZ, RL, RML and RMLF (n = 3)CC BY-NC-ND · PubMed Central
Fig. 2 RMLF relieves hypoxic TME and actively targets 4T1 cells. (a)Typical oxygen generation kinetics curves of RL, RML, RMLF and MnB in the presence of H2O2 ([Mn] = 10 µg/mL, [H2O2] = 1 mM) (b, d) Quantitative analysis of the fluorescence intensity of MnB and MnB with 100 µM H2O2 by Image J (n = 3). IFM images of 4T1 cells treated with MnB ([Mn] = 10 µg/mL) for 24 h with or without H2O2 (100 µM) and stained with RDPP as an O2 probe, respectively. The scale bar represents 200 μm. (c, e) Quantitative analysis of the HIF-1α fluorescence intensity of more than 100 cells in each group by Image J (n = 3). Hypoxia-relieving efficacy of RMLF (2 µM RudZ, [Mn] = 10 µg/mL) assessed by HIF-1α immunofluorescence. The scale bar represents 50 μm. (f, g) In vitro uptake of RudZ and different liposome-based samples (2 µM RudZ) on 4T1 cells analyzed by IFM. The scale bar represents 200 μm. Quantitative analysis of the fluorescence intensity of RudZ and different liposome samples by Image J (n = 3). *** indicates p < 0.001; **** indicates p < 0.0001
Fig. 2 RMLF relieves hypoxic TME and actively targets 4T1 cells. (a)Typical oxygen generation kinetics curves of RL, RML, RMLF and MnB in the presence of H2O2 ([Mn] = 10 µg/mL, [H2O2] = 1 mM) (b, d) Quantitative analysis of the fluorescence intensity of MnB and MnB with 100 µM H2O2 by Image J (n = 3). IFM images of 4T1 cells treated with MnB ([Mn] = 10 µg/mL) for 24 h with or without H2O2 (100 µM) and stained with RDPP as an O2 probe, respectively. The scale bar represents 200 μm. (c, e) Quantitative analysis of the HIF-1α fluorescence intensity of more than 100 cells in each group by Image J (n = 3). Hypoxia-relieving efficacy of RMLF (2 µM RudZ, [Mn] = 10 µg/mL) assessed by HIF-1α immunofluorescence. The scale bar represents 50 μm. (f, g) In vitro uptake of RudZ and different liposome-based samples (2 µM RudZ) on 4T1 cells analyzed by IFM. The scale bar represents 200 μm. Quantitative analysis of the fluorescence intensity of RudZ and different liposome samples by Image J (n = 3). *** indicates p < 0.001; **** indicates p < 0.0001CC BY-NC-ND · PubMed Central
Fig. 3 Evaluation of radiotherapy sensitizing activity of RMLF in vitro. (a) Cell viability of 4T1 cells treated with the RudZ (2 µM), CDDP (2 µM), MnB ([Mn] = 10 µg/mL), RML (2 µM RudZ, [Mn] = 10 µg/mL) and RMLF (2 µM RudZ, [Mn] = 10 µg/mL) (n = 3). The dose of X-ray is 4 Gy. (b, e) The quantitative analysis of survival fraction (SF) from clone formation under different treatments (n = 3). And optical photographs of clonogenic survival assay under different treatments. (c, f) Quantitative analysis of the γ-H2AX fluorescence intensity of more than 100 cells in each group by Image J (n = 3). The DNA damage effect of RMLF (2 µM RudZ, [Mn] = 10 µg/mL) was assessed by γ-H2AX immunofluorescence. The scale bars represent 200 μm. (d) Flow cytometry was employed to perform cell cycle analysis of 4T1 cells subjected to different treatments. *** indicates p < 0.001; **** indicates p < 0.0001
Fig. 3 Evaluation of radiotherapy sensitizing activity of RMLF in vitro. (a) Cell viability of 4T1 cells treated with the RudZ (2 µM), CDDP (2 µM), MnB ([Mn] = 10 µg/mL), RML (2 µM RudZ, [Mn] = 10 µg/mL) and RMLF (2 µM RudZ, [Mn] = 10 µg/mL) (n = 3). The dose of X-ray is 4 Gy. (b, e) The quantitative analysis of survival fraction (SF) from clone formation under different treatments (n = 3). And optical photographs of clonogenic survival assay under different treatments. (c, f) Quantitative analysis of the γ-H2AX fluorescence intensity of more than 100 cells in each group by Image J (n = 3). The DNA damage effect of RMLF (2 µM RudZ, [Mn] = 10 µg/mL) was assessed by γ-H2AX immunofluorescence. The scale bars represent 200 μm. (d) Flow cytometry was employed to perform cell cycle analysis of 4T1 cells subjected to different treatments. *** indicates p < 0.001; **** indicates p < 0.0001CC BY-NC-ND · PubMed Central
Fig. 4 RMLF induces oxidative damage to mtDNA and prompts its translocation to the cytoplasm, results in a dual activation of the cGAS-STING immune signaling pathway. (a) CLSM images of RudZ, RL, RMLF and Mito Tracker Green staining. The scale bar represents 40 μm. (b) PicoGreen staining was performed to analyze mtDNA damage. The scale bar represents 40 μm. (c) 8-OH-dG immunofluorescence staining was performed to analyze mtDNA damage. The scale bar represents 40 μm. (d) qRT-PCR analysis of the relative expression levels of cGAS-STING, NF-κB, IRF3 mRNA after different treatments of 4T1 cells (n = 3). (e) mtTFA antibody was used to distinguish mtDNA (TFAM-mtTFA Green) and Hoechst-stained nuclei, to detect the escape of mtDNA from mitochondria to the cytoplasm. The scale bar represents 40 μm and 10 μm. (g) qRT-PCR analysis of mtDNA escape levels in 4T1 cells supernatants after different treatments (n = 3). (f) Western blot analysis of the protein pathway associated with mtDNA release and activation of the cGAS-STING intrinsic immune signaling pathway in 4T1 cells. * indicates p < 0.05; ** indicates p < 0.01; *** indicates p < 0.001; **** indicates p < 0.0001
Fig. 4 RMLF induces oxidative damage to mtDNA and prompts its translocation to the cytoplasm, results in a dual activation of the cGAS-STING immune signaling pathway. (a) CLSM images of RudZ, RL, RMLF and Mito Tracker Green staining. The scale bar represents 40 μm. (b) PicoGreen staining was performed to analyze mtDNA damage. The scale bar represents 40 μm. (c) 8-OH-dG immunofluorescence staining was performed to analyze mtDNA damage. The scale bar represents 40 μm. (d) qRT-PCR analysis of the relative expression levels of cGAS-STING, NF-κB, IRF3 mRNA after different treatments of 4T1 cells (n = 3). (e) mtTFA antibody was used to distinguish mtDNA (TFAM-mtTFA Green) and Hoechst-stained nuclei, to detect the escape of mtDNA from mitochondria to the cytoplasm. The scale bar represents 40 μm and 10 μm. (g) qRT-PCR analysis of mtDNA escape levels in 4T1 cells supernatants after different treatments (n = 3). (f) Western blot analysis of the protein pathway associated with mtDNA release and activation of the cGAS-STING intrinsic immune signaling pathway in 4T1 cells. * indicates p < 0.05; ** indicates p < 0.01; *** indicates p < 0.001; **** indicates p < 0.0001CC BY-NC-ND · PubMed Central
Fig. 5 Evaluation of in vivo radioimmunotherapy. (a) Schematic design of in vivo radioimmunotherapy. (b) Relative tumor volumes change curve during various treatment (n = 5). (c) Tumor photos at the end of various treatments. (d) Tumor weights at the end of various treatments (n = 5). (e) Body weight of mice during various treatments (n = 5). (f) Quantification of the proportion of cells expressing CD80 in tumor draining lymph nodes at the end of treatment by flow cytometry (I). Quantification of the proportion of cells expressing CD86 and CD206 in tumor tissue at the end of treatment by flow cytometry (II, III). (g-j) The levels of 2’3’-cGAMP (g), TNF-α, IFN-β, and IL-6 (h, i, j) in tumors of different treatment groups of mice were analyzed by ELISA (n = 3). * indicates p < 0.05; ** indicates p < 0.01; *** indicates p < 0.001; **** indicates p < 0.0001
Fig. 5 Evaluation of in vivo radioimmunotherapy. (a) Schematic design of in vivo radioimmunotherapy. (b) Relative tumor volumes change curve during various treatment (n = 5). (c) Tumor photos at the end of various treatments. (d) Tumor weights at the end of various treatments (n = 5). (e) Body weight of mice during various treatments (n = 5). (f) Quantification of the proportion of cells expressing CD80 in tumor draining lymph nodes at the end of treatment by flow cytometry (I). Quantification of the proportion of cells expressing CD86 and CD206 in tumor tissue at the end of treatment by flow cytometry (II, III). (g-j) The levels of 2’3’-cGAMP (g), TNF-α, IFN-β, and IL-6 (h, i, j) in tumors of different treatment groups of mice were analyzed by ELISA (n = 3). * indicates p < 0.05; ** indicates p < 0.01; *** indicates p < 0.001; **** indicates p < 0.0001CC BY-NC-ND · PubMed Central
Fig. 6 Evaluation of long-term immune memory effects in vivo. (a) Schematic design of long-term immunological memory effect evaluation. (b) Relative tumor volume change curve during treatment (n = 5). (c)Tumor weights at the end of treatment (n = 5). (d) Tumor photos at the end of treatment. (e) Body weight of mice during treatment (n = 5). (f, g) The determination of effector memory T cells (CD45+CD3+CD4+CD44+CD62− and CD45+CD3+CD8+CD44+CD62−) and central memory T cells (CD45+CD3+CD4+CD44+CD62+ and CD45+CD3+CD8+ CD44+CD62+) in CD8+ T cells and CD4+ T cells in spleens. * indicates p < 0.05; ** indicates p < 0.01, **** indicates p < 0.0001
Fig. 6 Evaluation of long-term immune memory effects in vivo. (a) Schematic design of long-term immunological memory effect evaluation. (b) Relative tumor volume change curve during treatment (n = 5). (c)Tumor weights at the end of treatment (n = 5). (d) Tumor photos at the end of treatment. (e) Body weight of mice during treatment (n = 5). (f, g) The determination of effector memory T cells (CD45+CD3+CD4+CD44+CD62− and CD45+CD3+CD8+CD44+CD62−) and central memory T cells (CD45+CD3+CD4+CD44+CD62+ and CD45+CD3+CD8+ CD44+CD62+) in CD8+ T cells and CD4+ T cells in spleens. * indicates p < 0.05; ** indicates p < 0.01, **** indicates p < 0.0001CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Cited by

See all 9

Metadata

Authors
Peng, J., Quan, D.-L., Yang, G., Wei, L.-T., Yang, Z., Dong, Z.-Y., Zou, Y.-M., Hou, Y.-K., Chen, J.-X., Lv, L., & Sun, B.
Affiliations
  • The First Affiliated Hospital, Sun Yat-sen University (CN)
  • Southern Medical University Shenzhen Hospital (CN)
  • Jinan University (CN)
  • Southern Medical University (CN)
Corresponding author
  • Lv, Lin
  • Sun, Bin
Venue
Journal of Nanobiotechnology
Published
2024-11-27
Volume
22
Issue
1
Pages
735-735
ISSN
1477-3155 (ISSN-L)
OpenAlex
W4404731262
Cited by
9
References
63
Citations by year
2026: 6 · 2025: 3
FWCI
0.99
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Nanobiotechnology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • the Characteristic Innovation Projects of Colleges and Universities in Guangdong Province (2018KTSCX028)
  • the Open Funding of MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, Sun Yat-Sen University (BISC2022A03)
  • the Student Innovation and Entrepreneurship Training Program Project of Southern Medical University (S202212121191)
  • National Natural Science Foundation of China (82204415)
  • the Guangdong Basic and Applied Basic Research Foundation (2021A1515220187)
  • Guangdong Science and Technology Department of China (2023A1515012633)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Keywords
radioimmunotherapy, ruthenium(II) complexes, manganese dioxide nanoparticles, radiosensitization, reactive oxygen species, tumor hypoxia, cGAS-STING pathway, type I interferon signaling, radiation-induced immune response, tumor-associated macrophage polarization, cytotoxic T lymphocytes, breast cancer, nanocomposite drug delivery
MeSH terms
Multifunctional Nanoparticles, Animals, Breast Neoplasms, Female, Humans, Liposomes, Mice, Inbred BALB C, Oxides, Radiation-Sensitizing Agents, Ruthenium, Radioimmunotherapy, Reactive Oxygen Species, Manganese Compounds, Cell Line, Tumor, Mice, Nanoparticles, Nanocomposites, Coordination Complexes, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multifunctional nanocomposites utilizing ruthenium (II) complex/manganese (IV) dioxide nanoparticle for synergistic reinforcing radioimmunotherapy. https://app.cochat.ai/papers/10.1186/s12951-024-03013-2
The paper
Peng, J., Quan, D.-L., Yang, G., Wei, L.-T., Yang, Z., Dong, Z.-Y., Zou, Y.-M., Hou, Y.-K., Chen, J.-X., Lv, L., & Sun, B. (2024). Multifunctional nanocomposites utilizing ruthenium (II) complex/manganese (IV) dioxide nanoparticle for synergistic reinforcing radioimmunotherapy. Journal of Nanobiotechnology. https://doi.org/10.1186/s12951-024-03013-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.